Naogen Pharma is a radiopharmaceutical company installed in Nantes, France and aiming at developing innovative radiopharmaceutical agents in cardiology and oncology using radionuclides produced by high energy high intensity Arronax cyclotron.
Founded in september 2016 after completion of a research project termed Quanticardi and financed by French Public Bank and Pays de la Loire Region, the company developed in premises of Arronax site with private investor funds.
Its expertise relies on the availabilty and mastery of a rubidium-82 generator and an infuser necessary for the non-invasive diagnosis of myocardial ischemia in cardiology using Positron Emission Tomography (PET).
Pôle Bio Ouest
44800 Saint Herblain